Infusystems Holdings, Inc. · AMEX:INFU
Infusystems — Q1 2026 Earnings Presentation
12 slides from Infusystems's earnings presentation, May 7, 2026
Slide 1: InfuSystem Announces Financial Results for First Quarter 2026
May 7, 2026 InfuSystem Announces Financial Results for First Quarter 2026 Net Revenues of $33.7 million Representing a 3% Reduction from the Prior Year Net income of $1.0 million Adjusted EBITDA (non-GAAP) of $6.4 million Adjusted EBITDA (non-GAAP) margin expanded by 1% to 19% Reaffirms Full-Year 20
Slide 2: Management Discussion: Wound Care and ERP Go-Live
Adjusted EBITDA performance.” “Wound care continues to be an exciting growth engine for InfuSystem. First‑quarter net revenue reached $2.1 million, more than doubling year-over-year. While currently just 6% of total revenue, we believe the growth rate indicative of the new therapy’s potential. Rough
Slide 3: Device Solutions Revenue and Gross Profit
Device Solutions net revenue of $11.6 million decreased $2.4 million, or 17%, during the 2026 First Quarter compared to the 2025 First Quarter. This decrease included a reduction in biomedical services revenue of $1.3 million, equipment rentals of $0.4 million and equipment sales of $1.0 million. Th
Slide 4: Operating Expenses: Selling, Marketing and G&A
reduced gross margin by 1.9%. Higher wages were the result of typical annual merit and cost of living increases, however, the increase in the cost of health care benefits were significantly higher than amounts experience in prior years. Selling and marketing expenses for the 2026 First Quarter were
Slide 5: Liquidity and Net Debt
intensive such as wound care and sales of disposable medical supplies. Also during the three-month period ended March 31, 2026, the Company repurchased $0.8 million of its Common Stock. As of March 31, 2026, available liquidity totaled $57.1 million and consisted of $55.0 million in available borrow
Slide 6: Non-GAAP Financial Measures
EBITDA to net debt ratio. The Company believes that the non-GAAP financial measures presented in this press release provide useful information to the Company’s management, investors and other interested parties about the Company’s operating performance because they allow them to understand and compa
Slide 7: Forward-Looking Statements
The words “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “goal,” “expect,” “strategy,” “future,” “likely,” variations of such words, and other similar expressions, as they relate to the Company, are intended to identify forward-looking statements. Forward
Slide 8: Condensed Consolidated Statements of Operations and Segment Reporting
Interest expense (255) (336) Other income (expense) 82 (29) Income before income taxes 1,417 253 Provision for income taxes (400) (520) Net income (loss) $ 1,017 $ (267) Net income (loss) per share: Basic $ 0.05 $ (0.01) Diluted $ 0.05 $ (0.01) Weighted average shares outstanding: Basic 20,211,045 2
Slide 9: Adjusted EBITDA Reconciliation
Three Months Ended March 31, (in thousands) 2026 2025 GAAP net income (loss) $ 1,017 $ (267) Adjustments: Interest expense 255 336 Income tax provision 400 520 Depreciation 3,045 3,072 Amortization 209 248 Non-GAAP EBITDA $ 4,926 $ 3,909 Stock compensation costs 1,233 1,108 Medical equipment reserve
Slide 10: Consolidated Balance Sheets
(6) Represents expenses associated with a project to upgrade the Company’s information technology and business applications including a replacement of our main enterprise resource planning (“ERP”) application. The project was launched during the second quarter of 2024 and was completed during the fi
Slide 11: Balance Sheet Liabilities and Cash Flows
Long-term debt 19,646 19,625 Operating lease liabilities, net of current portion 3,120 3,427 Total liabilities 39,908 43,234 Stockholders’ equity: Preferred stock, $0.0001 par value: authorized 1,000,000 shares; none issued — — Common stock, $0.0001 par value: authorized 200,000,000 shares; 20,178,8
Slide 12: Consolidated Statements of Cash Flows
Other current assets (130) 126 Other assets 563 729 Changes in liabilities - (decrease)/increase: Accounts payable and other liabilities (3,328) (1,577) NET CASH PROVIDED BY OPERATING ACTIVITIES 970 1,780 INVESTING ACTIVITIES Purchase of medical equipment (1,680) (3,284) Purchase of property and equ